Mounjaro slimming (Lilly’s) is one step closer to becoming a magic molecule. If it has already demonstrated its ability to reduce the weight of people with obesity, now the American pharmaceutical company has managed to demonstrate in a clinical trial that it also prevents heart attacks and improves the quality of life of people who have suffered one. It should be remembered that the company carries out part of the manufacturing of this medicine in Spain.
The company has presented the results of tirzepatide (that is the name of Mounjaro’s molecule) from the Summit phase 3 clinical trial that demonstrate that its use significantly reduces the risk of developing events of heart failure in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. Additionally, patients treated with tirzepatide experienced notable improvements in heart failure symptoms and physical limitations. The results have been published in The New England Journal of Medicine simultaneously with a presentation at the American Heart Association (AHA) 2024 Scientific Sessions.
“Currently, no one doubts the unfavorable impact of obesity on heart failure with preserved ejection fraction, through the direct effect on the myocardium, affecting its relaxation and increasing chamber filling pressures, in addition to promoting inflammation. at a systemic and local level among other effects,” says Almudena Castro Conde, cardiologist and head of the Cardiac Rehabilitation Unit Section at the La Paz University Hospital in Madrid.
“The clinical trial gives us solid evidence of the benefit of tirzepatide in this profile of patients who until a few years ago lacked drugs that would improve their prognosis. At the same time, it is a call to action so that the medical community that treats these patients understands the close relationship between obesity and HFpEF and, therefore, its treatment is another pillar of our therapeutic arsenal,” adds the doctor. .
All key secondary endpoints were also met. and patients treated with tirzepatide demonstrated an improvement in their exercise capacity, walking approximately 30 meters further in six minutes than those receiving placebo (38.2 meters vs. 7.9 meters). Likewise, patients using tirzepatide saw an average reduction in body weight of 15.7%, compared to 2.2% in the placebo group2. Tirzepatide also significantly decreased high-sensitivity C-reactive protein (hsCRP), a key marker of systemic inflammation, by 43.4%, while the placebo group experienced a 3.5% decrease.
#addition #losing #weight #prevents #heart #attacks #drug #reduces #obesity #achieves #clinical #milestone
